News – Page 1131 – Endpoints News

Big Pharma CEOs push hard for tax reform and a proposed border levy

9 years ago

PMV Pharma gets a whopping $74M round to test a new p53 drug in humans

9 years ago

Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis

9 years ago

Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII

9 years ago

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

9 years ago

Buyout buzz swells for the giant Bristol-Myers after Carl Icahn makes an entrance, stage left

9 years ago

Cidara shares tank after lead antifungal program flops in PhII

9 years ago

Neovacs signs €65M China deal; Another biotech CEO chatters on about a possible buyout

9 years ago

Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review

9 years ago

Trevena says its PhIII pain drug program is a winner, but shares crater

9 years ago

Gilead bags Sarepta's priority review voucher for a discount, paying $125M

9 years ago

An FDA reform agenda: What would Commissioner Scott Gottlieb do in his first six months?

9 years ago

After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar’s intranasal version

9 years ago

Arix IPO raises £100M for new biotech investments; Santhera sets up shop in Massachusetts

9 years ago

Another price-gouging CEO proves the system is broken, underscoring need for principled reform at the FDA

9 years ago

Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well

9 years ago

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

9 years ago

AstraZeneca throws down the gauntlet with a PhIII victory in head-to-head PARP war with Tesaro

9 years ago

ArQule’s lead drug tivantinib flops again in PhIII liver cancer study

9 years ago

Sage CEO’s M&A chatter sparks a spike, and an awkward correction

9 years ago

Looking to an IPO? Rhythm raises $41M to pay for pivotal trials

9 years ago

Alkermes CEO Pops stays focused on 5461 filing plans; Shkreli gets booed at Harvard

9 years ago

With an extra $25M in hand, Dauntless maps the next stage of growth for the pipeline

9 years ago

Alexion shelves an early-stage Sanfilippo B drug, writes off $85M

9 years ago

First page Previous page 1128 1129 113011311132 1133 1134 Next page Last page